Pharmaceutical

Biostax and Immgenuity to expedite HIV immunotherapies development

Biostax and Immgenuity have entered into an agreement to expedite the development of new immunotherapeutics to treat HIV and other diseases.

Aug 30, 2023 - 20:00
Biostax and Immgenuity to expedite HIV immunotherapies development
Biostax and Immgenuity have entered into an agreement to expedite the development of new immunotherapeutics to treat HIV and other diseases.
Read the original article

Tags:

Previous Article

FibroGen’s pamrevlumab disappointing results marks second failure in a row

Next Article

EC grants approval to Merck’s Keytruda for gastric cancer

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AstriVax received €2.5 million government grant for thermostable vaccines

AstriVax received €2.5 million government grant for the...

May 30, 2023

FDA approves BridgeBio’s Attruby for ATTR-CM treatment

FDA approves BridgeBio’s Attruby for ATTR-CM treatment

Nov 25, 2024

Dechra Pharmaceuticals sees highest patent filings and grants during May in Q2 2024

Dechra Pharmaceuticals sees highest patent filings and ...

Jul 22, 2024